AXON
Wall Street's still in the building
JPMorgan Chase just took a little air out of Axon Enterprise’s valuation balloon, cutting its price target to $750 from $925. But before you start picturing a full-blown panic, the firm kept its Overweight rating in place — which is basically Wall Street for “we still like the story, just not at yesterday’s price.”
Why this matters
Axon has been on a tear, and when a stock’s already expensive, even a positive note can come with a reality check. JPMorgan’s move says the company still has appeal, but the bar for future upside is getting harder to clear. That matters if you’re holding the name, because rich valuations don’t leave much room for disappointment.
The plot twist: plenty of bulls, just a little less enthusiasm
JPMorgan isn’t alone in nudging expectations down. Other analysts have also trimmed their targets lately, even as the broader consensus stays at Moderate Buy. In other words, the Street still likes Axon’s moat, but it’s starting to sound more like a “show me” crowd than a “buy anything with a logo” crowd.
The real investor takeaway
Axon recently beat estimates, with $2.15 in EPS versus $1.60 expected and revenue up 38.5% year over year to $796.7 million. That’s solid. But when a stock is already trading at a hefty premium, strong results aren’t enough — investors also want the next chapter to look just as shiny.
Big picture: Axon’s still a Wall Street favorite, but the target cut is a reminder that even the cool kids can get a valuation haircut.